Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19
Open Access
- 10 April 2020
- journal article
- letter
- Published by Elsevier BV in Journal of Infection
- Vol. 81 (2), 318-356
- https://doi.org/10.1016/j.jinf.2020.03.044
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Coronavirus 2019-nCoV: A brief perspective from the front lineJournal of Infection, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJama-Journal Of The American Medical Association, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A reviewJournal of Infection and Public Health, 2018
- Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza InfectionEBioMedicine, 2017
- Intravenous Immunoglobulin and Mortality in Pneumonia Patients With Septic Shock: An Observational Nationwide StudyClinical Infectious Diseases, 2015
- Hyperimmune IV Immunoglobulin TreatmentSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Immunoglobulin A Modulates Inflammatory Responses in an In Vitro Model of PneumoniaThe Journal of Trauma and Acute Care Surgery, 2005
- Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiencyJournal of Allergy and Clinical Immunology, 2002